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This paper summarizes the responses of a groupof panelists to the topic of pharrnacoeconom-
ics of lipid-lowering therapies, introduced by Gerry
Oster [Oster, this issue]. Moderated by William F.
McGhan, the panel included Alistair McGuire,
Talat Ashraf, and J. Sanford Schwartz. Reactions
and comments of meeting participants follow.
Alistair McGuire: From his review of the eco-
nomic benefits of lipid-lowering therapies, Gerry
Oster is absolutely right that such treatment is rel-
atively cost-effective. In the West of Scotland Cor-
onary Prevention Study (WOSCOPS) [1], the bot-
tom-line results within the United Kingdom (UK)
setting relate to about $34-$35,000 per life-year
gained. For the high-risk patients, those who meet
the European atherosclerotic guidelines and have
extraordinarily high levels of lipids in their blood,
the cost-effectiveness ratio comes out to about
$23-$24,000 per life-year gained, These take into
account cost offsets within the UK, so that if you
avert a coronary heart disease event, you avert the
costs associated with it. Treatment therapy costs
are much higher in the United States (US), so the
cost-offsets will be higher and the ratios will be
decreased accordingly.
Another point to address from Gerry Oster's
talk is that we've just undertaken an analysis of lit-
erature in this area. This review piggybacked onto
the US General Accounting Office Report that came
out in 1996. Forty-six clinical trials in this area are
reported, with the WOSCOPS [1] study just squeez-
ing in, but not the Scandinavian Simvastatin Sur-
vival Study (4S) [2] nor the Cholesterol and Re-
current Events (CARE) study [3]. A review of the
evidence revealed 74 economic analyses based on
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these 46 trials, Only 37 of them could truly be con-
sidered economic studies in any true sense of the
definition. Twelve of them were related to screening
and 25 to pharmacological interventions; only five
considered secondary prevention, with most consid-
ering primary prevention. Twenty of the 25 studies
considered life-years gained, and 17 of those were
based on the Framingham regression coefficients,
using Framingham logistic equations and regres-
sors to model out the impact in life-years gained.
The results coming out of the 2S studies that consid-
ered pharmacological intervention vary markedly. If
we take the cost per life-year gained, depending on
the type of intervention, assumptions by age, risk
factor, duration of therapy, sex, and the type of
modeling undertaken, the cost per life-year gained
ranged between $22,000 right up to $362,000 per
life-year gained. It is only in the last year that
we've had any good long-term evidence on pri-
mary prevention, and in the last two years that
we've had any good long-term evidence on sec-
ondary prevention. These can now provide infor-
mation on mortality gains on which we can base
economic models, and these models have really
confirmed how cost-effective lipid-lowering ther-
apy is in both primary and secondary prevention.
Talat Ashraf: Dr. Oster left us with a question
concerning the role of models based on Framing-
ham data in lipid-lowering evaluations, compared
to data derived from clinical trials and the rela-
tionship between the two. Of course, Dr. Oster is
correct in that there have been no significant stud-
ies comparing outcomes predicted from models
and those determined from clinical trials. How-
ever, there are problems with both trials and mod-
els. One of the problems with clinical trials is that
the event rates are very small, even in large trials.
Therefore the trial data has to be placed in a larger
context and other data has to be added to model
long-term outcomes. With models, one of the prob-
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lems is their continued reliance on Framingham
data. Can we continue using Framingham data
even though there are many problems with it?
Also, the models that rely on this data produce a
large degree of variance and do not incorporate
some factors (e.g., patient compliance) that impact
the observed cost-effectiveness ratios. I believe we
have to begin making decisions about how these
issues should be faced in the future.
J. Sanford Schwartz: I have some comments about
the cost-effectiveness ratios determined in recent
clinical trials and about the future use of models.
In the 4S study, depending on whether you look at
managed care or Medicare hospital costs, and
what the patients are paying out of pocket for the
drug or whether they are buying it under a con-
tracted price, the economic data show a cost per
life-year saved that varies from being cost-saving to
approximately $50,000 or $60,000. However, tak-
ing realistic estimates-for example, using Medi-
care hospital costs and a weighted market cost of
drugs-the cost-effectiveness ratio runs between
$5000 and $10,000 per life-year saved. Now, in
some groups it's actually a little more cost-effec-
tive, surprisingly in the elderly, because although
they have shorter life spans they also have many
more events, which more than offset costs. I don't
think that what drives the differences in cost-effec-
tiveness between 45 and W05COPS is the cost
differential between the United States and Can-
ada. Instead, I believe it's due to the relative risks
of the populations being treated, and the 45 pa-
tients were a higher risk population. The cost-
effectiveness ratios for the CARE study would be
expected to lie somewhere between the 45 and
W05COP5 ratios. Of course, the important ques-
tion in these studies is when does it not become
cost-effective to use drugs? One of the successes of
modeling has been the ability to identify popula-
tions that derive the maximum benefit from lipid-
lowering therapies at an acceptable cost. I think
there has been some remarkable work done using
models, and the data has held up remarkably well.
Furthermore, I believe there is still a role for mod-
els, mainly because the lipid trials are all time lim-
ited. The trials usually last from 5 to 7 years, yet
this is a lifetime therapy and it is in this capacity of
lifetime extension that modeling can still play a
significant role. In the future, however, models
should also be sensitive to real-life clinical prac-
tice, and factors such as patient compliance will
have to be incorporated into the analyses, as will
the ability to generalize clinical trial data from one
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country to another. For example, how well does
data from a clinical trial in Scotland reflect out-
comes in patients from other countries?
The relationship between the degree of low den-
sity lipoprotein (LDL) cholesterol reduction and
coronary heart disease (CHD) is also a crucial ques-
tion for models. This issue is still controversial, but
whether one assumes that more cholesterol reduc-
tion is better or that enough is enough at a certain
point, the modeling results will nevertheless change.
Results will also change as a result of competition
in the lipid-lowering therapy marketplace. If the
costs of drugs decrease, we will have to go back
and reexamine cost-effectiveness analyses, because
there may be situations where there is a downward
pressure on prices and at the same time an upward
progress in the effectiveness of LDL cholesterol-
lowering therapies.
The difference in effectiveness between statins
is also an important issue. Right now this is a very
competitive market and I believe we have to make
every effort to ensure that we have access to all fu-
ture trial data. A company may sponsor their own
clinical trials but in the process may leave out im-
portant clinical data that we could effectively use.
Therefore, I think it is important that we have ac-
cess to as much data as possible in future studies.
In any case, it is always better to have some of the
analyses carried out by groups who have no vested
interest in the results. There is a possibility that in
the future, in this highly competitive market, we
may miss an opportunity to learn a lot from future
studies, unless some of these barriers come down.
Moderator: Those are excellent comments. What
I'd like to do now is to open the discussion up to
the audience for questions or comments.
Speaker 1: Are indirect costs-the costs of lost
wages and earnings due to morbidity and prema-
ture mortality-included in some of these studies?
It has also been suggested that the year-of-life-saved
metric should be abandoned. Could we have some
discussion on that?
Alistair McGuire: In answer to the first question,
about 95% of the studies we have reviewed did not
include indirect costs or benefits. They're called in-
direct costs and benefits partly because they're sec-
ondary. The main benefit from a lipid-lowering in-
tervention is that it's prolonging life, and you need
to do that before you can work. In terms of the
life-years saved, I think to abandon this is a mis-
understanding of what the concept is. If you only
take the mortality gains within the time span of the
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clinical trial, then the benefit is relatively small.
Much of the therapy's benefit, however, is in reduc-
ing clinical events, and we have to model these
clinical events out past the end of the trial to fully
capture the impact on life expectancy. That's why
we want to continue using life-years saved as a
primary measure of benefit, and if you don't do
this then everything else is secondary.
Speaker 2: Can I just comment very briefly with
respect to the two issues of indirect costs and cost
per life-year saved? In our piece in the American
Journal of Public Health we did look at indirect
cost-savings associated with cholesterol reduction,
but I would agree that it's not typically done. One
reason why it's not typically done is because of the
possibility of double counting. If you count life-
years saved and then add indirect cost-savings, in
effect these benefits are being counted twice. Con-
cerning the use of the cost per life-year saved,
most of the major evaluations that have been con-
ducted incorporate not only the impact of therapy
in reducing the number of fatal events, but also
the excess mortality associated with the nonfatal
events that are prevented. So they do address both
these parameters in a cost-per-life-year-saved metric.
What they don't take into account, however, is the
impact of coronary artery disease or the benefits
of therapy on quality of life. There are no good
preference-weighted measures or cost-per-quality-
adjusted-life-year estimates for lipid-lowering thera-
pies, and I think this is an area that should be
addressed.
Speaker 3: I would like to raise the issue of the dis-
tinction in the world of healthcare delivery between
the pharmacy budget and the other outcomes. Also,
by extension, what is the role of delivery systems,
such as health maintenance organizations (HMOs),
Medicare, and Medicaid, in terms of defining bud-
gets for these drugs?
J. Sanford Schwartz: I think one of the big prob-
lems we have in the United States is misaligned in-
centives. As long as we pay pharmacy budget man-
agers by how much they cut a pharmacy budget, as
long as we look at costs in these different silos,
we're going to have a very difficult time doing any-
thing except in those medical areas that have short-
term payoffs. Misaligned incentives can be over-
come if we can get the right people interested in the
area. We've seen it with breast cancer in the
United States, and I think we're seeing it to some de-
gree with lipid-lowering therapies. The same prob-
lem also exists to a lesser extent in the United King-
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dam, which is interesting, because even when you
have the same government paying the social and
medical costs, if they come out of different bud-
gets, it also causes problems.
If I could just add one thing on indirect costs, I
don't think the only problem, or even the main
problem, with indirect costs is double counting. I
think there are also real problems in valuation.
For example, what do we do with people who are
retired? The best thing to do economically in indi-
rect costs is to let everybody die the day they re-
tire, or as shortly thereafter as possible, because
these individuals are not generating income but in-
stead are using income. This, of course, raises both
philosophical as well as measurement issues. There-
fore, we who work in this area have to be cautious
in the way studies are presented because different
people might interpret the data in different ways.
To overcome this problem there is going to be a
real need for education in outcomes research, at
both the clinical level and at the administrative level
so that people are more aware of the information
that can be derived from these studies.
Peter Dalley: I am not sure that the recent trials
actually validate the models because, essentially,
in the pre-eS, CARE, WOSCOPS era, the models
were saying that if cholesterol-lowering works,
then these are the anticipated economic benefits.
In the post-trial era, now that there is proof that
these drugs work, the models are used to project
what the economic benefits will be. The point is
that even after trials, models are still required be-
cause the trials do not capture the long-term health-
care consequences of intervention, nor do they cap-
ture mortality beyond a certain point.
Talat Ashraf: There are two different kinds of
models. One uses the basic Framingham data to
actually model event rates, while the other takes
an actual event and models the subsequent reper-
cussions of that event. With the latter approach,
the model has more reliability since it is based on
actual observed events.
William Castelli: I have a comment on the cost-
per-year-of-life-saved issue. The problem with this
approach is that a lot of the data is not used. It's
not the people who die with heart attacks that have
a large impact on the medical system, it's those in-
dividuals who survive and now require angioplasty
or bypass surgery. Even the patients with angina
impose a large economic burden since present-day
antianginal drugs can cost $5 to $10 a day. The
point is that an economic model cannot ignore all
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these direct care costs, and this doesn't even ac-
count for those individuals who lose their jobs and
are no longer economically viable. A model that
only assesses years of life saved, without assessing
the impact of reductions in morbidity, is inade-
quate for healrhcare administrators.
Gerry Oster: Let me respond to the last point be-
cause I think there may be a basic misunderstand-
ing of terminology. When we talk about cost per
life-year saved in pharmacoeconomic evaluations,
the numerator contains three components: the
cost of the drug therapy itself, plus the cost of
treating side-effects associated with that therapy,
minus the cost-savings associated with events that
are avoided. So, in fact, in all the evaluations I
summarized, and in all the major lipid studies of
which I'm aware, the numerator does, in fact, take
into account cost-savings associated with the non-
fatal events avoided. Therefore, just because the
metric is cost per life-year saved, this does not im-
ply that the only costs considered in the analysis
are those of drug therapy.
]. Sanford Schwartz: In response, I think what you
have said is important. However, the other techni-
cal point, which isn't clear to everyone, is the dis-
counting of costs in these analyses. So, in other
words, if a revascularization procedure is delayed
from 1990 to 1995, we have to deduct the value of
having delayed the procedure. To an individual pa-
tient this delay has real value, but unfortunately
the cost-per-year-of-life-saved metric, until very re-
cently, has been the only available way to quantify
these situations. I think the general feeling now is
that the preferred metric is the cost per quality-
adjusted life-year, which takes into account all the
parameters you noted. The real challenge now is to
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be able to get better metrics for assessing quality-
adjusted life-years in lipid-lowering therapies.
William Castelli: The per-year-of-life-saved model
worked well in renal dialysis because if patients
stopped therapy they died 2 weeks later. But this
is not the case when patients stop taking preven-
tive therapy for coronary disease. In this situation,
if a patient has a heart attack, only 15% will die if
they are under the age of 65, and 25% if they are
over 65 years of age. However, the vast majority
of the patients live, perhaps half of them chroni-
cally ill, and it's in this population that the real
economic benefits of lipid-lowering therapies can
be realized.
Moderator: This concludes the reactor panel and
open forum session on some major issues in lipid-
lowering pharmacoeconomic studies. I encourage
you to continue dialogue on this very important
topic.
This article was preparedwith the assistance of BioMed-
Com Consultants inc., Montreal,Canada.
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